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HBeAg were co-incubated for 6h, compared to that of before
stimulation, expression of B7-H1 on CD14+ cells increased, ex-
pression of TLR2 decreased, expression of B7-H1 and PD-1 on
CD4+ and CD8+ T cells increased signiﬁcantly, expression of cos-
timulatory molecules CD28 on CD4+ cells decreased;Inﬂammatory
factor TNF-α and anti-viral cytokine IFN-γ of HBeAg-stimulated
PBMC from HBeAg-negative CHB patients, increased and reduced
respectively.
Conclusion: By up-regulating expression of B7-H1 and PD-
1,HBeAg may inhibit expression of TLR2 on CD14+ cells, reduce
expression of costimulatory molecules CD28 on T lymphocyte,
inhibit polarization of Th cells, and reduce active secretion of
anti-viral factor of patients, which leaded to function of speciﬁc
cell-mediated immunity became low, thereby clearance of virus
by T lymphocyte were suppressed, which eventually resulted in
persistence of HBV infection.
PP-108 Detecting hepatitis B virus large surface protein in
patients with chronic hepatitis B: a clinical study
Zheng-lin Wu*, Peng Zhuang, Xue-dong Lu, Jian Liu,
Xiao-qiang Zhong. The Fourth People’s Hospital of Shenzhen
Objective: To investigate the clinical signiﬁcance of hepatitis B
virus large protein (HBLP) detection in prediction of HBV DNA
replication and the effect of anti-viral treatment.
Methods: The Serum samples were collected from 90 patients
with HBV infection before and after anti-viral treatment. HBV
DNA level was quantitatively detected using real-time poly-
merase chain reaction. HBLP was measured by enzymelinked
immunosorbent assay (ELISA). The collected data were analyzed
by bivariate correlations method.
Results: There was no signiﬁcant difference between the de-
tectable rates of HBV DNA and HBV-LP in 90 blood samples before
treatment (p>0.05); The levels of serum HBV-LP was positively
correlated with HBV DNA copies during anti-viral treatment
(r=0.857, P=0.000). The OD value of HBV-LP and the copies of
HBV-DNA decreased in the same trend along with treatment.
Conclusion: HBLP expression can reﬂect the state of HBV DNA
replication. The decrease of HBLP and HBV-DNA during the anti-
viral treatment could estimate the HBV replication state and
predict the effect of anti-viral treatment.
PP-109 A study for HBsAg routine test negative results
Zheng-lin Wu*, Jian Liu, Xiao-qiang Zhong, Guang-cheng Lin,
Xue-dong Lu. The Fourth People’s Hospital of Shenzhen
Objective: To see the false HBsAg negative results for serum
samples in daily work and to improve the clinical laboratory tests
quality.
Methods: Four hundreds HBsAg negative stochastic serum sam-
ples were collected from the copy tubes in daily work for
detecting hepatitis B Virus markers (HBVM) with national ELISA
reagent kits divided into 200 samples with HBsAb negative and
200 positive and put them −20° frostily. HBsAg markers were
counterchecked with other two adding kinds of national reagent
and American MONOLISA HBsAg ULTRA reagents (total 4 kinds)
at the 400 samples and ﬁltrated the positive samples. At the
last ﬁltrated samples, HBV DNA levels were doubly quantitative
analyzed with ﬂuorescence quantitative PCR (FQ-PCR) and taking
the mean results.
Results:We educed the conform HBsAg negative results from the
three kinds of national reagents but ﬁve positive results from
the American reagents in repeating HBsAg detection at the 200
HBsAb negative samples. No positive results were checked out
from the 200 HBsAb positive samples with national or foreign
reagents. The HBV DNA FQ-PCR quantitative results were all
positive but less than 500 copies/ml.
Conclusion: The sensitive level of the HBsAg routine test ELISA
reagents is generally on the low side and easily bring on the false
HBsAg negative results and the false results are more frequently
from the HBsAb negative people. This maybe connected with
occult HBV infection, we should attach importance to the HBVM
counterchecking work at these people.
PP-110 Detecting hepatitis B virus large surface protein
to ﬁltrate the occult HBV infection
Zheng-lin Wu*, Jian Liu, Xiao-qiang Zhong, Guang-cheng Lin,
Xue-dong Lu. The Fourth People’s Hospital of Shenzhen
Objective: Detecting hepatitis B virus large surface protein
(HBLP) with serological method to ﬁltrate the occult HBV infec-
tion and study the clinical detection strategy.
Methods: Two thousands HBsAg negative stochastic serum sam-
ples were collected from the copy tubes in daily work to detect
hepatitis B Virus markers (HBVM) with national ELISA reagent kits
and put them –20° frostily. The 2000 samples were detected with
HBLP and ﬁltrated the positive samples. HBsAg markers were
doubly counterchecked with other two adding kinds of national
ELISA reagent kits (total 3 kinds) at the ﬁltrated samples. The
last samples were doubly tested again with American MONOLISA
HBsAg ULTRA reagents. HBV DNA levels were quantitative an-
alyzed with ﬂuorescence quantitative PCR (FQ-PCR) and taking
the mean results.
Results: Fifteen HBLP positive samples were detected out from
the 2000 serum samples. The conform negative results were
educed from the three kinds of national reagents but conform
positive results from the American reagents in repeating HBsAg
detection at the 15 samples. The HBV DNA FQ-PCR quantitative
results were all positive but less than 500 copies/ml.
Conclusion: The false HBsAg negative results for serum samples
are more generally from national reagents than from impor-
tations and HBLP results may be positive in these samples.
Detecting HBLP marker is propitious to ﬁltrate the occult HBV
infection. This study provided a kind of serological reference
for actively searching for the detecting strategy in occult HBV
infection ﬁeld.
PP-111 Evolution of hepatitis B virus in a chronic
HBV-infected patient over 2 years
Tao Shen*, Yun Lian Zou, Xin Min Yan, Hong Dong. The Institute
of Basic Medicine
Background: Evaluation of a 3-year evolution of hepatitis B virus
in a chronically infected patient was conducted.
Methods: Clinic data and HBV DNA load(s) in serum were de-
tected at three time points (1 day, 6 month and 31 month), HBV
isolates were obtained at each time.The full-length HBV genome
was cloned and 26 clones including three time points were
randomly selected, sequenced and phylogenetically analyzed.
Results: All of the 26 clones belonged to subgenotype C2. 13 nu-
cleotides in this subset of clones were found to be different from
the published sequences of genotype C of HBV. During the 3-year
evolution, nucleotides T361A, C930A, C2351T/A2353T, C2444T
were the mutations been kept in and from minor to major while
C339T and T770C were the new point mutations at the 3rd time
point (31 month). Short fragment deletion (nt2849 to 2867) in the
preS gene became dominant at the 31-month time point and had
a trend to lead to large fragment deletion, which may produce
presumptive P/S fusion proteins or truncated preS proteins. At
the third time point, the patient’s serum ALT, HBeAg and load of
HBV DNA varied greatly.
Conclusion: The evolutionary data of HBV may provide clues for
the interpretation of the course of HBV chronic infection and
progressive pathology of liver diseases.
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PP-112 Analysis of ﬁve HBeAg-positive patients with
Chinese herb Kuanxiongjiedu grain anti-HBV
infection treatment
Lequan Min*,1, Yanling Liu2, Jianghe Wang2, Huiwen Hong2,
Suyun Ma2. 1University of Science and Technology Beijing;
2Beijing Xiyuan Hospital, Chinese Traditional Medical Research
Institute of China
Background and objectives: The objectives of the research are
to observe the efﬁcacy of the Chinese Herb Kuanxiongjiedu Grain
(CHKG, consists of 12 ingredients) treatment for the patients
whose HBV DNA levels over 106 copies/mL and analysis the
variations of the patients’ hepatocyte.
Methods: Five patients with HBeAg-positive are selected. They
have baseline ALTs: 22.3∼285U/L, HBV DNAs: 2.1×106∼2.8×108
copies/mL. The patients received CHKG two times daily (24g
each time) for 32 weeks. The ALT and HBV DNA tests were
implemented every two weeks in the ﬁrst three months, and
taken every four weeks in the following months. A Ultrasound
Scanner was used to scan the patients and a normal person’s
livers. The mean and standard deviation of the gray levels of the
normal person’s scanned liver image are selected as the standard
of normal liver.
Results: At the week 32, one patient’s HBV DNA was below 1000
copies/mL and had normal ALT; three patient’s HBV DNAs and
ALTs have no signiﬁcant changes; one patient’s HBV DNAs have
signiﬁcant changes. Except the ﬁrst patient, the patients’ normal
liver pixels increased 14% ∼ 51%.
Conclusion: The CHKG may help to recovered the chronic HBV
patients’ damaged hepatocyte even the patients’ virus levels
were not be suppressed during the therapy. Further investigation
should be implemented.
Acknowledgments: This work is jointly supported by the Na-
tional 11-5 Key Special Project of China (No. 2008ZX10502) and
the NNSF of China (No. 60674059).
PP-113 Sequence analysis and replication ﬁtness of the
complete hepatitis B virus genome in patients
with chronic hepatitis B
Dong Ji *, Yan Liu. Viral Hepatitis Research Laboratory, Institute
of Infectious Diseases, 302 Hospital of PLA, Beijing, China
Objective: To analyze the complete HBV genome in patients and
evaluate its replication capacity.
Fig. 1. Schematic diagram of the point mutations analyzed in the study. In
the ﬁrst part of the ﬁgure, the nunber on the top of the full HBV genome
refers to the EcoRI site (3215/0). Position of the four open reading frames
(ORFs) encoding preC/core, preS1/preS2/S, polymerase (Pol), and X protein
are shown by the gray rectangle and the arrow indicates the transcription
direction. The four cis-elements (enhancers and promoters) are indicated
by the open triangle. The numbers under the full HBV genome represent the
nucleotide positions of the studied mutations. In the second part of the
ﬁgure are listed amino acid mutations in both polymerase (RT domain) and
envelope genes-associated domains (S domain).
Methods: The full-length HBV genome ampliﬁcation, cloning,
and sequencing were preformed. Genotype and mutation sites
related to antiviral agents were analyzed, and site-directed mu-
tagenesis was performed on interested sites. The full-length HBV
genomes were transfected into HepG2 and Huh-7 cell lines. 72 h
after transfection, expression of HBsAg was detected with ELISA,
quantitation of intracellular HBV replicative intermediates were
examined by qPCR.
Results: 12 different clones were obtained. several mutation
sites, such as A181V/S, V84M, were identiﬁed, and the better
management of 5 patients was developed.
Fig. 2. Relative replication yield of HBV mutants.
Conclusion: Vector-free replication assay is an approach to
determine the phenotype of clinical HBV strains, which could be-
come an important tool for the management of patient infected
with HBV.
PP-114 Correlation factors involved in therapeutic
efﬁcacy of adefovir dipivoxil for chronic hepatitis
B with YMDD mutation
Yuan-wang Qiu*, Xiang-hu Jiang, Li-hua Huang. Wuxi Infectious
Disease Hospital
Background: To investigate the correlation factors associated
with the therapeutic efﬁcacy of adefovir dipivoxil for chronic
hepatitis B with YMDD mutation.
Methods: 92 patients were enrolled and treated with adefovir
dipivoxil for 48 weeks, Logistic regression analysis was used
to identify some possible correlation factors associated with
therapeutic efﬁcacy.
Results: Patients who achieved undetectable HBV DNA at week
48 of the treatment were found to have a lower baseline HBV
DNA levels compared with those who did not achieve,and the
same result in patients who achieved HBeAg seroconversion
and serum alanine aminotransferase (ALT) normalization. There
were signiﬁcant difference between patients whose baseline ALT
levels ≤1 ULN,HBV DNA levels ≤5.0 lgcopies/mL and patients
whose baseline serum ALT levels >1 ULN,HBV DNA levels >5.0
lgcopies/mL in undetectable HBV DNA (χ2=17.321, P<0.001),
HBeAg seroconversion (χ2=3.88, P=0.049) and ALT normalization
rates (χ2=25.526, P<0.001) after 48-week treatment. Logistic
regression analysis indicated the baseline HBV DNA levels, unde-
tectable serum HBV DNA by PCR at week 24, and undetectable
serum YMDD mutation at week 12 were correlation factors of
therapeutic efﬁcacy at week 48.
Conclusion: Better response at week 48 has signiﬁcantly asso-
